logo-loader
viewOptiBiotix Health PLC

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated.
CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020.
News here too on Sweetbiotix and just how serious O'Hara is about market listing on NASDAQ. The firm, which is now in 24 countries, is looking to extend its reach into new application areas such as hypertension, immune health and gut health.

Quick facts: OptiBiotix Health PLC

Price: 49.5 GBX

AIM:OPTI
Market: AIM
Market Cap: £42.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix Health agrees exclusive deal for LPLDL in USA and Canada

Steve Prescott, the chief executive of ProBiotix, which is a wholly-owned subsidiary of OptiBiotix Health PLC (LON:OPTI), caught up for a brief chat with Proactive London's Andrew Scott after announcing they've signed a distributor agreement with Advanced NutriSolutions Inc./Select Ingredient...

1 week, 4 days ago

2 min read